Characterisation of a novel Drosophila melanogaster testis specific PP1 inhibitor related to mammalian inhibitor-2: identification of the site of interaction with PP1  by Helps, Nicholas R. et al.
Characterisation of a novel Drosophila melanogaster testis speci¢c
PP1 inhibitor related to mammalian inhibitor-2:
identi¢cation of the site of interaction with PP1
Nicholas R. Helps*, Cornillia Vergidou1, Terri Gaskell2, Patricia T.W. Cohen
Medical Research Council Protein Phosphorylation Unit, Department of Biochemistry, University of Dundee, Dundee DD1 5EH, UK
Received 24 September 1998; received in revised form 1 October 1998
Abstract A novel Drosophila melanogaster protein, termed
inhibitor-t, that bears 41% sequence similarity to human protein
phosphatase inhibitor-2 has been identified using human protein
phosphatase 1 (PP1) in the yeast two hybrid system. Inhibitor-t
mRNA is detected in adult males, larvae and pupae and the 184
amino acid thermostable protein located only in testis. The gene
for inhibitor-t maps to cytological location 86F1 on the third
chromosome. Bacterially expressed inhibitor-t specifically in-
hibits both mammalian and D. melanogaster PP1 catalytic
subunits with an IC50 of approximately 200 nM. A motif
-FEX1X2RK-, conserved between inhibitor-t, inhibitor-2 and its
Saccharomyces cerevisiae homologue Glc8, is demonstrated to be
required for binding to PP1.
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1. Introduction
Protein phosphorylation is a ubiquitous mechanism by
which eukaryotic cellular functions are regulated, the control
of protein phosphatases being an integral part of this process
[1,2]. To achieve this regulation, the catalytic subunit of PP1
(PP1c) associates with numerous regulatory subunits in vivo,
the function of which is to target PP1c to speci¢c subcellular
locations, alter its substrate speci¢city and to allow its activity
to be modi¢ed by extracellular signals [3]. Targeting subunits
that have been characterised and allow PP1c to regulate the
enzymes of glycogen metabolism include the GM subunit that
targets PP1c to both glycogen particles and the sarcoplasmic
reticulum in striated muscle [4,5], the GL subunit that targets
PP1c to glycogen in liver [6], as well as two more widely
distributed glycogen targeting subunits PP1R5/PTG [7,8]
and PP1R6 [9]. Myosin targeting subunits that enable PP1c
to regulate myosin contractility have been characterised in
skeletal [10] and smooth [11] muscle. Other PP1c interacting
subunits that are likely to allow PP1c to regulate a wide vari-
ety of processes include the nuclear proteins NIPP-1 [12] and
p99/PNUTS [13,14], which may bind to RNA, an RNA splic-
ing factor PSF1 [15], sds22, which is required for exit from
mitosis [16], and the retinoblastoma protein [17]. The riboso-
mal proteins L5 [18] and RIPP1 [19], the p53 binding protein
53BP2 [20], spinophilin, which is present in dendrites [21,22],
the microtubule motor KLP38B [23], phosphofructokinase
[24] and the g134.5 of Herpes simplex virus 1 that in£uences
protein synthesis [25] have also been shown to bind PP1c.
Interaction of the di¡erent regulatory subunits with PP1c is
mutually exclusive, an observation recently explained by the
discovery that a short motif -(R/K)(V/I)XF- present in the
majority (but not all) of these subunits was su⁄cient for bind-
ing to PP1c [26,27].
In addition to the above regulatory subunits, PP1c binds to
a number of small cytosolic inhibitor proteins including inhib-
itor-1 (I-1), inhibitor-2 (I-2), DARPP-32 (reviewed in [1,28])
and CPI17 [29], which inhibit PP1c activity at nanomolar
concentrations. Although I-1 and DARPP-32 bind to PP1c
via the sequence -KIQF-, the site of I-2 binding to PP1c is
unknown.
In an attempt to uncover novel regulatory subunits of PP1
we have performed yeast two hybrid screens using the human
PP1Q1 catalytic subunit, which has identi¢ed several human
proteins including I-2 [30] and 53BP2 [20]. In this communi-
cation we describe the identi¢cation of a novel Drosophila
melanogaster testis speci¢c PP1 inhibitor using the yeast two
hybrid screen. This inhibitor shares sequence similarity with
mammalian I-2 that identi¢es a novel short motif required for
the binding of I-2 and related proteins to PP1.
2. Materials and methods
2.1. Identi¢cation of D. melanogaster PP1 interacting proteins using
the yeast two hybrid system
Microbial strains and methods for the yeast two hybrid screen using
PP1 as bait were as previously described [30]. To isolate Drosophila
proteins capable of interacting with PP1, the yeast strain Y190 con-
taining a pAS2-PP1Q1 plasmid was transformed with DNA from a
pACT library containing D. melanogaster third instar larval cDNA
sequences. After growth on selection medium for 12 days, 10 colonies
representing 0.008% of the cells transformed were obtained. The
pACT plasmids from all 10 clones were recovered into Escherichia
coli and their cDNA inserts, termed PP1D1^PP1D10, sequenced.
2.2. General methods
Oligonucleotides were synthesised by Miss Audrey Gough (Univer-
sity of Dundee) on an Applied Biosystems model 394 DNA synthes-
iser. DNA sequencing was performed on an Applied Biosystems 373A
automated DNA sequencer using Taq dye terminator cycle sequenc-
ing. Screening of 1.5U105 pfu of a D. melanogaster Canton S genomic
library constructed in bacteriophage V EMBL-3 SP6/T7 vector (Clon-
tech, Palo Alto, CA) with a 600 bp EcoRI fragment of from the 5P end
of the PP1D6 cDNA was performed under high stringency conditions.
A 4 kb EcoRI fragment and a 2.2 kb EcoRI-XhoI fragment present
in three of four positive genomic clones identi¢ed were subcloned
into pBluescript KS and sequenced. Total RNA was puri¢ed from
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D. melanogaster (Oregon R strain) developmental stages and subjected
to formaldehyde gel electrophoresis and Northern blotting as de-
scribed in [31] using ‘Rapid-hyb’ bu¡er (Amersham Life Science,
Bucks, UK).
D. melanogaster protein extracts were prepared and immunological
analyses performed as in [31]. Extracts were heated at 100‡C as de-
scribed for E. coli extracts (Section 2.3).
2.3. Bacterial expression and puri¢cation of inhibitor-t and production
of antibodies
The 2.2 kb genomic EcoRI-XhoI fragment in pBluescript KS which
contained the entire open reading frame (ORF) of inhibitor-t was
used as a template in a polymerase chain reaction (PCR) with the
oligonucleotide primers 5P-GCGCCATATGCATAAGAACTTCAA-
AAGTCTG-3P and 5P-GCGCGTCGACTAACCGCCAAAACCCTT-
GG-3P that incorporate NdeI and SalI restriction endonuclease sites
(underlined) at the initiating and terminating codons of the ORF
respectively. The PCR product was cleaved with these enzymes, in-
serted into the same sites of the E. coli expression vector pT7-7 [32] to
generate plasmid pT7-inhibitor-t and sequenced. Following expression
in E. coli in the presence of 100 WM IPTG for 4 h, the bacteria were
treated as for I-2 [30], except that bu¡er A was 50 mM Tris-HCl, pH
7.5, 1 mM EDTA, 0.1 mM EGTA, 0.02% (v/v) Brij 35, 0.1% (v/v) 2-
mercaptoethanol plus 0.1 mM phenylmethylsulphonyl £uoride
(PMSF) and 1 mM benzamidine. The supernatant obtained was ap-
plied to a Mono S HR 5/5 column (Pharmacia Ltd, Milton Keynes,
UK), which was developed with a 25 ml 0^400 mM linear NaCl
gradient in bu¡er A at room temperature. Inhibitor-t, which eluted
at 290 mM NaCl, was concentrated using a Centricon 10 (Amicon,
Beverly, MA) and stored at 370‡C. To generate a fusion between I-2
and inhibitor-t, the human I-2 cDNA was used in a PCR with primers
5P-GCGCCATATGGCGGCCTCGACGGCCTC-3P and 5P-CCGGC-
CGCGGCCTCGTCGACATTCCCACGGGGCTG-3P that generated
NdeI and SacII sites (underlined) at the initiating methionine and
downstream from amino acid 38 respectively. The SacII containing
primer enabled mutation of an endogenous SacII site within the I-2
cDNA. The PCR product was cloned into the pT7-inhibitor-t con-
struct using these sites and sequenced. Expression and puri¢cation of
the fusion protein was performed as for inhibitor-t. A single peak of I-
2/I-t fusion protein eluted at 180 mM NaCl. Phe133 within the I-2/I-t
protein was mutated to Ala using the ‘QuikChange’ (Stratagene) site-
directed mutagenesis kit and the mutated protein puri¢ed as described
for I-2/I-t.
Antibodies against inhibitor-t were raised in sheep at the Scottish
Antibody Production Unit (Carluke, Lanarkshire, UK) using the full
length protein expressed in E. coli or synthetic peptides (HKNFKSL-
QNTNPSNC and CDQNNIKFSKGFGG) conjugated to keyhole
limpet haemocyanin. Antibodies raised against the whole protein
were a⁄nity puri¢ed using either the full length protein or two glu-
tathione S-transferase (GST) fusion proteins containing amino acids
1^92 or 120^184 of inhibitor-t and antibodies against synthetic pep-
tides were a⁄nity puri¢ed as previously described [33].
2.4. Expression of PP1 catalytic subunits in E. coli
Human PP1Q1 was expressed and puri¢ed as described in [34]. Dro-
sophila PP1^87B catalytic subunit was expressed using the PP1^87B
cDNA in pBluescript KS as a template in a PCR with oligonucleotide
primers 5P-GCGCCATATGGGCGACGTGATGAATATC-3P and
T7 to introduce a NdeI site (underlined) at the initiating methionine,
then cloned into the plasmid pCR2.1 using the ‘TOPO’ cloning kit
(Invitrogen) and sequenced. The construct was cleaved with NdeI and
XbaI (present in the polylinker of pCR2.1) and inserted into the same
sites of plasmid pCW to generate the construct pCWPP1^87B. PP1^
87B was expressed in E. coli and puri¢ed as in [34]. Homogeneous
PP1^87B had a speci¢c activity of 48 U/mg against phosphorylase a in
the presence of 0.5 mM Mn2 ions.
2.5. Protein phosphatase and inhibitor assays
Phosphatase assays were performed in the presence of 0.5 mM
Mn2 (PP1Q1 and PP1^87B) or in the absence of divalent cations
(PP2Ac) using 32P-labelled rabbit skeletal muscle glycogen phospho-
rylase [35] or 32P-phosphorylated myosin P-light chains [26]. One unit
of phosphatase activity is that amount of enzyme that catalyses the
release of 1 Wmol [32P] phosphate/min from phosphorylase a. Micro-
cystin-LR, okadaic acid, inhibitor-2 and inhibitor-t were assayed as in
[36].
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Fig. 1. Comparison of D. melanogaster inhibitor-t (top), human I-2 (middle) and S. cerevisiae Glc8 (bottom) protein sequences. Identical resi-
dues are boxed in black, while conserved residues are boxed in grey. Threonines 59 of inhibitor-t, 72 of human I-2, and 118 of Glc8 are indi-
cated (*), while other areas of sequence conservation are indicated by brackets. The comparison was created using the program PILEUP (Ge-
netics Computer Group, Madison, WI, USA) and shading was performed using the program BOXSHADE (v3.21, K. Hofmann and M.
Baron).
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3. Results
3.1. Identi¢cation and sequence of PP1 inhibitor-t
Ten yeast colonies positive on selective medium were ob-
tained from a yeast two hybrid analysis using human PP1Q1 to
screen a D. melanogaster larval cDNA expression library.
Plasmids from two of these colonies, designated PP1D6 and
PP1D10, contained overlapping cDNA sequences encoding
181 and 174 amino acids respectively of a novel protein. Since
the PP1D6 and PP1D10 cDNAs did not contain the full cod-
ing sequence of the novel protein, genomic clones were iden-
ti¢ed from a D. melanogaster genomic library by screening
with a probe from the 5P end of the PP1D6 cDNA. A 2.2
kb EcoRI-XhoI genomic fragment contained the full open
reading frame of the gene, which has been submitted to the
GenEMBL database under the accession number AJ006867.
The complete open reading frame encodes a protein of 184
amino acids with a predicted molecular weight of 20.5 kDa. A
consensus Drosophila transcription start site sequence
(GTCAGTT [37]) is found between nucleotides 361 and
367 with respect to the initiating methionine and is preceded
by a number of TATA promoter elements. Within the 3P un-
translated region of PP1D6 and PP1D10 cDNAs as well as in
the gene sequence there exist three consensus polyadenylation
signals.
Database searching revealed no proteins with high sequence
identity to the 20.5 kDa Drosophila protein. However, it did
show 21% identity (41% similarity) to PP1 inhibitor-2 (I-2)
[30,38] and 18% identity (34% similarity) to its yeast homo-
logue Glc8 [39] (Fig. 1) in pairwise comparisons using the
GAP algorithm (Genetic Computer Group, Madison, WI,
USA). These ¢gures are comparable to those for I-2 and
Glc8 (26% identity and 43% similarity). The novel 20.5 kDa
Drosophila protein was therefore termed PP1 inhibitor-t (I-t)
since, unlike I-2, it was also shown to be testis speci¢c (see
below).
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Fig. 2. Expression of inhibitor-t mRNA during the Drosophila life
cycle. 20 Wg of total RNA from the developmental stages shown
was separated on a denaturing 1% agarose gel and transferred to
nylon membrane. The membrane was probed with 32P-radiolabelled
600 bp EcoRI fragment from the PP1D6 cDNA (A). It was subse-
quently probed with cDNAs for human L-actin (Clontech) (C) and
D. melanogaster protein phosphatase 1^87B [40] (D), since these
mRNAs are expressed fairly uniformly during development. B:
RNA stained with ethidium bromide and visualised by ultraviolet
light. Lanes are: E1, 0^4 h embryos; E2, 4^24 h embryos; L, third
instar larvae; P, pupae; F, adult female; M, adult male. Sizes are
in kb. Transcripts are indicated (arrows).
Fig. 3. Immunoblotting of D. melanogaster protein extracts and pu-
ri¢cation of inhibitor-t expressed in E. coli. A: D. melanogaster ex-
tracts were separated on a 12.5% acrylamide SDS-PAGE, trans-
ferred to nitroclellulose membrane and probed with a⁄nity-puri¢ed
anti-inhibitor-t whole protein antibody at a concentration of 200
ng/ml, followed by anti-sheep-HRP conjugate. Signal was detected
using enhanced chemiluminescence. Lanes are: 1, 40 Wg adult male
D. melanogaster whole body minus testis soluble extract; 2, superna-
tant from 40 Wg of this extract after heating at 100‡C and centrifu-
gation; 3, pellet from the heated extract; 4, 40 Wg of adult male D.
melanogaster testis soluble extract; 5, supernatant from 40 Wg of
this extract after heating at 100‡C and centrifugation; 6, pellet from
the heated extract; 7, 100 pg of inhibitor-t expressed in E. coli. In-
hibitor-t is indicated (arrow). B: Samples from the stages of puri¢-
cation shown were separated on a 12.5% SDS-PAGE and stained
with Coomassie brilliant blue R250 to visualise the proteins. Lanes
are: M, markers; 1, 20 Wg of whole cell soluble extract from E. coli
expressing inhibitor-t; 2, 2.5 Wg of supernatant from the extract
heated at 100‡C; 3, 2 Wg of inhibitor-t eluted from Mono S. Marker
sizes are in kDa. Inhibitor-t is indicated (arrow).
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3.2. Expression of PP1 inhibitor-t mRNA and protein in
D. melanogaster
Analysis of RNA during the D. melanogaster life cycle re-
vealed that an inhibitor-t cDNA probe hybridised with a 1.1
kb mRNA transcript that could be detected in larvae, pupae
and adult males (Fig. 2A). Longer exposures failed to detect
this transcript in either embryos or adult females. Since larvae
and pupae were not sexed prior to extracting RNA, it is likely
that the signal seen at these developmental stages represents a
mRNA that is male speci¢c as in the adult. Approximately
equal amounts of RNA were present in all lanes (Fig. 2B).
Antibodies against the inhibitor-t protein failed to detect a
band of the correct size in D. melanogaster extracts made from
whole male £ies (data not shown), but when separate extracts
were prepared from testes and the remainder of the male £ies,
the inhibitor-t antibodies recognised a protein of 25 kDa in
the testis extract (Fig. 3A, lane 4) and not in the extract made
from the other tissues (Fig. 3A, lane 1). Since inhibitor-2 is
known to be thermostable, we examined whether endogenous
inhibitor-t also possessed this property by heating extracts at
100‡C. The 25 kDa band seen in whole testis extract was
present in the soluble fraction after heating (Fig. 3A, lane
5). Proteins that crossreacted with the anti-inhibitor-t anti-
bodies, which were abundant as judged by Ponceau S staining,
were not seen since they were insoluble after heat treatment
(Fig. 3A, lane 6). Comparison of the immunostaining intensity
for inhibitor-t in the heat treated testis supernatant (Fig. 3A,
lane 5) with the positive control (Fig. 3A, lane 7) indicates
that inhibitor-t represents only approximately 0.0025% of the
total testis protein. Even if the level of inhibitor-t is estimated
from the band migrating at that position in the total soluble
extract prior to heat treatment (Fig. 3A, lane 4) this estimate
only rises to 0.005% of the total protein. To con¢rm that the
25 kDa band seen in testis extracts was inhibitor-t, anti-inhib-
itor-t antibody was pre-incubated with a 20-fold molar excess
of bacterially expressed inhibitor-t prior to adding to the im-
munoblot. This treatment completely abolished the signal in
the testis extract (not shown).
Although endogenous inhibitor-t migrates with an apparent
molecular mass of 25 kDa, which is larger than was expected
from its sequence (20.5 kDa), the apparent size is identical to
that of the bacterially expressed inhibitor-t (Fig. 3A, lane 7).
It should also be noted that mammalian I-1 and I-2 migrate
anomalously on SDS-PAGE [1,38]. A speci¢c subcellular im-
munolocalisation of inhibitor-t in D. melanogaster testis could
not be obtained, presumably due to the low abundance of
inhibitor-t.
3.3. Properties of inhibitor-t
Bacterially expressed inhibitor-t was puri¢ed utilising its
thermostable nature and fast protein liquid chromatography
on Mono S, eluting as a single peak of protein that was
homogeneous as judged by SDS-PAGE (Fig. 3B). Inhibitor-
t was found to inhibit both human PP1Q1 and D. melanogaster
PP1-87B (the major PP1 catalytic subunit isoform [40]) with
an IC50 of approximately 200 nM when mammalian phos-
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Fig. 4. Properties of expressed PP1-87B phosphatase and e¡ect of inhibitor-t on activity of various phosphatase catalytic subunits compared
with known inhibitors of PP1Q1 and PP1^87B. Phosphatase activity is given as a percentage of the maximum obtained in the absence of any in-
hibitors. A: E¡ect of human I-2 (triangles), okadaic acid (circles) and microcystin-LR (boxes) on the phosphorylase a phosphatase activity of
PP1^87B catalytic subunit. B: Inhibition of phosphorylase a phosphatase activity of PP1Q1 (circles) and PP1^87B (triangles) by inhibitor-t
(closed symbols), I-2/I-t wild type fusion protein (open symbols) and I-2/I-t Phe133Ala mutant fusion protein (shaded symbols). C: Inhibition of
phosphorylase a (triangles) and myosin P-light chain (circles) phosphatase activity of PP1Q1 by inhibitor-t. D: Inhibition of phosphorylase a
phosphatase activity of PP2Ac by I-2 (circles) and inhibitor-t (triangles). In all assays the maximal release of 32P from substrates in the absence
of inhibitors was 10%.
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phorylase a was used as a substrate (Fig. 4B). Inhibitor-t was
unable to inhibit the catalytic subunit of human PP2A (Fig.
4D), or the catalytic subunit of the D. melanogaster testis
speci¢c PP1-like phosphatase PPY (data not shown) [31]
over the concentration range that inhibited PP1c, indicating
that the inhibition was speci¢c for PP1c. When phosphoryl-
ated myosin P-light chains were used as a substrate, inhibitor-
t was found to inhibit PP1 more potently with an IC50 of
approximately 20 nM (Fig. 4C), suggesting that the degree
of inhibition is partially substrate dependent. Previous dele-
tion studies indicate that the amino-terminal 35 residues of I-2
are involved in the inhibition of PP1 [41]. From the sequence
comparison (Fig. 1), it can be seen that residues 1^20 of in-
hibitor-t are aligned with residues 1^38 of I-2. We therefore
replaced the amino-terminal 20 residues of inhibitor-t with 38
residues from the amino-terminus of human I-2. Fig. 4B
shows that the I-2/I-t fusion protein is over 10-fold better
than inhibitor-t at inhibiting both PP1Q1 and PP1^87B, with
an IC50 of approximately 10 nM when phosphorylase a is the
substrate.
Comparison of inhibitor-t with I-2 and Glc8 shows that a
group of basic residues and a region of acidic residues towards
the C-termini of all three proteins are highly conserved
(marked in Fig. 1). Previous results have shown that residues
after Leu146 of I-2 are not required for inhibition of PP1 [41],
thus eliminating the acidic region as essential for inhibition of
or binding to PP1. We therefore chose to mutate the con-
served Phe133 residue (Phe115 in inhibitor-t) in the I-2/I-t fu-
sion protein to Ala and then to study the e⁄cacy of this
protein as a PP1 inhibitor. Fig. 4B shows that the mutant I-
2/I-t protein exhibited an IC50 of about 2 WM against PP1Q1
when phosphorylase a was used as a substrate. This is 200-
fold higher than for the wild type protein and indicates that
this Phe residue within inhibitor-t, and therefore probably
also within I-2 and Glc8, is important for inhibition or bind-
ing of PP1. Immunoprecipitation experiments with pure PP1Q1
and the I-2/I-t fusion proteins showed that, whilst the wild
type I-2/I-t fusion protein was e⁄ciently co-immunoprecipi-
tated with PP1Q1, the Phe133Ala mutant failed to be recovered
in the pellet (data not shown). This result shows that Phe115 of
inhibitor-t and the corresponding residues of I-2 and Glc8 are
likely to be important for binding of these proteins to PP1.
I-2 can be phosphorylated on Thr72 by glycogen synthase
kinase-3 (GSK-3) [42], which results in activation of a com-
plex of PP1c and I-2 termed PP1I. Since inhibitor-t contains
sequence around Thr59 that show high conservation to that
surrounding Thr72 in I-2, we examined the phosphorylation of
the former. GSK-3 phosphorylated inhibitor-t up to a stoichi-
ometry of 1 mol phosphate/mol inhibitor-t and protein se-
quencing identi¢ed a single phosphorylated residue that was
Thr59 (data not shown).
3.4. Localisation of the inhibitor-t gene on D. melanogaster
chromosomes
In situ hybridisation to D. melanogaster polytene chromo-
somes revealed that the inhibitor-t gene is present at 86F1 on
the third chromosome (data not shown). A search of the Fly-
Base database (University of Indiana) did not reveal any can-
didate mutants at this location and analysis of a panel of P
element insertions mapping to this location (kindly provided
by Dr P. Deak, University of Dundee) failed to identify an
insertion event within the inhibitor-t gene.
4. Discussion
We have previously used the yeast two hybrid system to
identify mammalian proteins capable of interacting with hu-
man PP1c [20,30]. Given the high level of sequence identity
between mammalian and D. melanogaster PP1cs [40], it
seemed likely that a mammalian PP1c would interact with
D. melanogaster PP1c binding proteins in the yeast two hybrid
system. Two out of the 10 Drosophila clones identi¢ed in the
screen with human PP1Q1 contained overlapping sequences,
indicating that they encoded a bona ¢de PP1 binding protein.
The corresponding gene sequence speci¢ed a novel protein
with sequence similarity to mammalian I-2 and its Saccharo-
myces cerevisiae homologue Glc8. I-2 is a speci¢c inhibitor of
PP1c that has been identi¢ed in a wide range of eukaryotic
organisms [1,38]. However, inhibitor-t is not the D. mela-
nogaster homologue of I-2, since we have shown that inhib-
itor-t is testis speci¢c, while I-2 has been identi¢ed in all
mammalian tissues so far examined [43,44]. In addition, I-2
activity has been detected in D. melanogaster head extracts as
well as in the whole organism [45]. Inhibitor-t may therefore
represent a specialised form of I-2 that is required for some
aspect of PP1c regulation in the testis. A testis-speci¢c isoform
of mammalian PP1, termed PP1Q2, has been identi¢ed [46].
PP1Q1 and PP1Q2 are produced from the same gene by alter-
native mRNA splicing, resulting in them possessing di¡erent
C-termini, but PP1Q1 has a wide tissue distribution [46]. D.
melanogaster possesses four isoforms of PP1c [40], although it
remains to be seen whether any of these are enriched in testis.
Although inhibitor-t does speci¢cally inhibit PP1c, its IC50
of 200 nM with phosphorylase a as substrate is around two
orders of magnitude higher than that of I-2 (IC50W2 nM).
However, the IC50 of Glc8 was found to be at least one order
of magnitude higher than that measured for I-2 [47]. In addi-
tion, given that inhibitor-t is not the D. melanogaster homo-
logue of mammalian I-2 and may play an alternative role in
the regulation of PP1c function from I-2, the higher inhibition
constant is not necessarily of concern. The e¡ect of inhibitor-t
on PP1c activity is also substrate dependent, a much lower
IC50 (V20 nM) being measured when phosphorylated myosin
P-light chains were used as substrate.
Previous truncation studies have suggested that the N-ter-
minal 1^35 amino acids of I-2 are important for potent inhib-
ition of PP1c [41], although an alteration in the truncated I-2
conformation could not be ruled out. We show that a chimae-
ric protein consisting of the ¢rst 38 amino acids of I-2 fused to
residues 19^184 of inhibitor-t is a much better inhibitor of
PP1 than inhibitor-t itself, demonstrating that these residues
of I-2 are indeed crucial for potent inhibition and may possess
a low a⁄nity binding site. However, the N-terminal 38 resi-
dues of I-2 are insu⁄cient to maintain binding of the I-2/I-t
Phe-Ala mutant to PP1.
Comparison of the structures of inhibitor-t, I-2 and Glc8 is
of interest because conservation of amino acids across evolu-
tionarily diverse species may identify functionally important
regions. The region immediately around Thr72 of I-2 that is
phosphorylated by GSK-3 [42] and MAP kinase [48], is con-
served in inhibitor-t and Glc8. This phosphorylation event is
critical for the activation of an inactive complex of PP1 and I-
2 (termed PP1I), which is postulated to represent a pool of
PP1 maintained ready for targeting subunits to interact with
when required [1,2]. More recently, it has been demonstrated
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that complex formation of PP1 and I-2 followed by phospho-
rylation of Thr72 by GSK-3 is required for the correct folding
of bacterially expressed PP1, suggesting that it may be re-
quired for the folding of newly synthesised PP1 into its native
conformation in vivo [34,49]. Phosphorylation of Thr72 by
MAPK has been postulated to play a role in the activation
of cytosolic PP1 by growth factors [48]. Here, we have shown
that inhibitor-t can be phosphorylated on Thr59 (correspond-
ing to Thr72 in I-2) by GSK-3 in vitro. It therefore seems
likely that inhibitor-t will be phosphorylated on Thr59 in
vivo and that this will have implications for its function.
Other regions that are conserved between inhibitor-t, I-2
and Glc8 might be expected to be important in binding to
PP1 and/or weak inhibition of PP1. Two regions exist towards
the C-terminus of inhibitor-t that are also conserved in I-2
and Glc8 (Fig. 1). Previous studies on I-2 indicate that the
second, acidic, region is not necessary for inhibition of PP1,
but may be important for activation of PP1/I-2 complexes by
GSK-3 [41]. This suggests that the ¢rst conserved region (res-
idues 140^145 in I-2) could be a PP1 binding motif with the
consensus sequence -FEX1X2RK-. Mutation of the conserved
Phe residue within this motif in the I-2/I-t fusion protein re-
sulted in almost complete loss of inhibition of PP1 by this
chimaeric inhibitor protein. Furthermore, we have shown
that mutated I-2/I-t is unable to bind to PP1, thus explaining
the loss of inhibition and more importantly implicating the
-FEX1X2RK- motif in the association of PP1 with I-2, inhib-
itor-t and Glc8, although there may be some restrictions
on the amino acids that can be tolerated at X1 and X2.
Over half the known PP1 binding proteins interact with PP1
via an -(R/K)(V/I)XF- motif or slight variation thereof [13]. It
will be interesting to determine if the -FEX1X2RK- motif is
used by some other PP1 binding proteins.
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